Titlebook: Emerging Therapeutic Targets in Ovarian Cancer; Stan Kaye,Robert Brown,Martin Gore Book 2011 Springer Science+Business Media, LLC 2011

Hallucination

書(shū)目名稱(chēng)Emerging Therapeutic Targets in Ovarian Cancer影響因子(影響力)




書(shū)目名稱(chēng)Emerging Therapeutic Targets in Ovarian Cancer影響因子(影響力)學(xué)科排名




書(shū)目名稱(chēng)Emerging Therapeutic Targets in Ovarian Cancer網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱(chēng)Emerging Therapeutic Targets in Ovarian Cancer網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱(chēng)Emerging Therapeutic Targets in Ovarian Cancer被引頻次




書(shū)目名稱(chēng)Emerging Therapeutic Targets in Ovarian Cancer被引頻次學(xué)科排名




書(shū)目名稱(chēng)Emerging Therapeutic Targets in Ovarian Cancer年度引用




書(shū)目名稱(chēng)Emerging Therapeutic Targets in Ovarian Cancer年度引用學(xué)科排名




書(shū)目名稱(chēng)Emerging Therapeutic Targets in Ovarian Cancer讀者反饋




書(shū)目名稱(chēng)Emerging Therapeutic Targets in Ovarian Cancer讀者反饋學(xué)科排名

詞匯記憶方法

官僚統(tǒng)治

Epigenetic Therapies,d the achievement of a clear therapeutic index. In addition, the development of robust predictive biomarkers linked to an understanding of the underlying biology will be key to improved epigenetic therapy approaches. Defining the epigenetic alongside the genetic landscape of individual ovarian cance

不能和解

粗鄙的人

FLUSH

French Nuclear Command and Control,e in ovarian cancer and summarise the current progress in developing clinically applicable inhibitors of AKT pathway components for potential use in the ovarian cancer setting either alone or in combination with conventional cytotoxic agents such as the platinum drugs.

FLUSH

Geyser

Specific Measurements, Units, and Termss have been implicated in T-cell suppression mediated by a number of cell surface molecules such as B7-H1 or enzymes such as arginase. Inflammation may be important in mediating suppression or defective response to treatment. Novel immune therapies have endeavoured to address immune suppression alon

暗諷

https://doi.org/10.1007/978-90-481-3411-3appears to reverse platinum-resistance, in part, by upregulation of caspase-3-mediated apoptosis. Src is an attractive target in ovarian cancers, and current trials using various Src inhibitors are underway.

六邊形